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Tracking hematopoietic stem cells and their progeny using
whole-genome sequencing
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Biology, University of York, York, United Kingdom;
c
Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Hills Road,
Cambridge, United Kingdom;
d
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Despite decades of progress in our understanding of hematopoiesis through the study of
animal models and transplantation in humans, investigating physiological human hema-
topoiesis directly has remained challenging. Questions on the clonal structure of the
human hematopoietic stem cell (HSC) pool, such as “how many HSCs are there?” and
“do all HSC clones actively produce all blood cell types in equal proportions?” remain
open. These questions have inherent value for understanding normal human physiol-
ogy, but also directly inform our comprehension of the process by which the system is
subverted to drive diseases of the blood, in particular blood cancers and bone marrow
failure syndromes. The critical link between normal and abnormal hematopoiesis is
perhaps best illustrated by the recent discovery of clonal hematopoiesis in healthy peo-
ple with no abnormal blood parameters. In such individuals, large clones derived from
single cells are present and are dominant relative to their normal counterparts, but
their presence does not necessitate abnormal blood cell production. Intriguingly, how-
ever, these individuals are also at a significantly greater risk of developing leukemias
and of cardiovascular events, underscoring the importance of understanding how blood
stem cell clones compete against each other. © 2020 ISEH – Society for Hematology
and Stem Cells. Published by Elsevier Inc. This is an open access article under the CC
BY license. (http://creativecommons.org/licenses/by/4.0/)
Despite decades of progress in our understanding of
hematopoiesis through the study of animal models and
transplantation in humans, investigating physiological
human hematopoiesis directly has remained challenging.
Questions on the clonal structure of the human hemato-
poietic stem cell (HSC) pool, such as “how many HSCs
are there?” and “do all HSC clones actively produce all
blood cell types in equal proportions?” remain open.
These questions have inherent value for understanding
normal human physiology, but also directly inform our
comprehension of the process by which the system is sub-
verted to drive diseases of the blood, in particular blood
cancers and bone marrow failure syndromes. The critical
link between normal and abnormal hematopoiesis is per-
haps best illustrated by the recent discovery of clonal
hematopoiesis in healthy people with no abnormal blood
parameters [1−3]. In such individuals, large clones
derived from single cells are present and are dominant rel-
ative to their normal counterparts, but their presence does
not necessitate abnormal blood cell production. Intrigu-
ingly, however, these individuals are also at a significantly
greater risk of developing leukemias and of cardiovascular
events [4,5], underscoring the importance of understanding
how blood stem cell clones compete against each other.
To determine what is abnormal, we first need to
understand the range of clone size distributions that
should be considered “normal.” Does clonal hematopoi-
esis simply represent the detectable tail of a distribu-
tion of clone sizes across the whole population (in the
same way that patients with high blood pressure are
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the tip of a normal distribution of blood pressure), or
does clonal hematopoiesis represent a qualitatively dis-
tinct state? The presence of somatic mutations in genes
that are also found in myeloid malignancies (e.g.,
TET2, DNMT3A) suggests the latter, but a number of
possible scenarios could explain their existence
(Figure 1).
As clonal hematopoiesis is covered in other articles
in this collection [2,3,6], we focus this review on
recent studies that have used whole-genome sequencing
to track clonal dynamics in unperturbed human hema-
topoiesis and touch upon future applications of the
approach in studying how aberrations in clonal dynam-
ics are evidenced in disease.
Methods to track HSCs
Studying the behavior of stem cell clones requires a way of
tracking them independently of one another. A considerable
number of approaches in animal models or in humans under-
going HSC transplantation have been devised, dating back to
the use of chromosomal [7] and enzymatic [8] markers to
affirm clonal origin [9]. Using irradiation to induce traceable
clonal marks, Becker et al. [10], Siminovitch et al. [11], and
Wu et al. [12] serially transplanted bone marrow cells from
mice and were able to demonstrate formally that the same
clonal unit could generate cells of both the myeloid and
lymphoid lineages. The whole-genome sequencing-based
approaches discussed later in this review, which use somatic
mutations to track cells, hark back to these original experi-
ments using chromosomal markers.
A more experimentally tractable method of following mul-
tiple clones was developed in the 1980s in which cells labeled
with retroviral barcodes or by unique viral integration sites
were transplanted into irradiated recipients [13,14]. Barcodes
could be found in all lineages, after transplantation into a sec-
ond mouse, they could be found again, indicating that the
transplanted cells were primitive and capable of creating
daughter stem cells [15]. In these transplantation experiments,
only a handful of stem and progenitor cells were found to be
responsible for the majority of the blood produced in the sal-
vaged animal [16,17], and these efforts culminated with the
remarkable result that transplantation of even a single
mouse [18] or human [19] HSC could be sufficient to recon-
stitute long-term multilineage hematopoiesis in mice. That a
small number of HSCs can reconstitute long-term multilineage
hematopoiesis in the transplantation setting, however, does not
mean that such a small number of HSCs are actually driving
the entirety of hematopoiesis in a physiological setting. More-
over, when large numbers of marked hematopoietic stem and
progenitor cells are transplanted into animals, blood produc-
tion remains polyclonal over long periods, with hundreds to
thousands of unique markers detected years after the trans-
plant [20−22].
Tracking cells via transplantation is associated with the disad-
vantage that the stress associated with the conditions of trans-
plantation may affect the way that the transplanted cells behave.
Certain cells that behave physiologically as HSCs may not do so
in transplantation, and vice versa, or the dynamics of the system
may be perturbed. Indeed, experiments in mice comparing in
vivo labeling with transplantation suggest that only a fraction of
the cells that would have behaved as HSCs would have
engrafted successfully in vivo [23].
Recent work exploiting advances in inducible genetic
labeling in mice to mark HSCs in vivo have begun to address
these issues [24]. One of these approaches used an inducible
sleeping beauty transposon system to label cells uniquely at
a specific timepoint [25,26]. This technique marks stem and
progenitor cells in vivo, allowing some of the first high-reso-
lution insights into unperturbed hematopoiesis. Months after
labeling, when the shortest-lived progenitors will have
exhausted, transposon tags were detected in peripheral blood
fractions. Tags were frequently shared across different differ-
entiated blood cell types, indicating that—in unperturbed
mice—most of the marked cells had multilineage outputs
[26]. Longitudinal follow-up revealed that tags were rarely
shared across different timepoints. One explanation for this
is that different stem cell clones take turns producing blood
Figure 1. Numerous possible routes to clonal hematopoiesis. (A)
Model A depicts what would happen if the clone in question has
expanded in size in an independent fashion (i.e., increased self-
renewal) without affecting or being affected by the normal stem cell
pool, thus increasing the total number of stem cells. (B) Model B
depicts what would happen if the clone actively competes with the
normal stem cell pool to take up a larger share of the total stem cell
number without actually changing that number. (C) Model C depicts
what would happen if the stem cell pool is decreasing in size, but
the clone in question displays greater resilience and represents a
greater proportion of the total stem cell pool not because it has
expanded greatly, but rather because the other stem cells have been
depleted more (i.e., the denominator shrinks). In all cases, a static
measurement of the clone would show an »60%−70% contribution
of the clone but the cellular mechanism would be very different.
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one after another (i.e., clonal succession) [27]. A potentially
more plausible explanation is that there are so many HSC
clones that the limited sampling of peripheral blood would
be unlikely to find the same tag across multiple timepoints,
even if the tag were always present in blood cells across all
timepoints. A second sophisticated method of marking cells
uniquely in vivo used a polylox recombination system to
generate random combinations of molecular cassettes [28].
The combinatorial diversity is such that the same sequence
of cassettes is highly unlikely to occur in different cell line-
ages, thereby enabling the labeling of embryonic cells when
HSCs first emerge. After birth, many barcodes were detected,
indicating that the adult HSC compartment is a mosaic of at
least hundreds of embryonic clones, again mostly with multi-
lineage output. As multiple adult HSC clones are nested
within embryonic clones, the number of embryonic clones
forms an extreme lower bound for the number of active
HSCs. Inferences about HSC clonal structure can also be
drawn from population-level analyses [23,29], which have
also supported the notion of large numbers of HSCs contrib-
uting to hematopoiesis. After permanent induction of the
expression of yellow fluorescent protein in 1% of immuno-
phenotypic HSCs and all their descendants, limiting dilution
analysis estimated that »30% of immunophenotypic HSCs
contributed to hematopoiesis over a mouse’s lifetime [23].
Perhaps one of the most important contributions of these
studies was the evidence that bone marrow transplantation,
the gold standard HSC functional assay, vastly underesti-
mates the functional output and mature cell production of
multipotent progenitor cells [23]. This does not mean that
HSCs are not ultimately responsible for the maintenance of
day-to-day hematopoiesis, but it does suggest that the gap
between HSC and multilineage progenitor with respect to
clone durability might not be as large as previously postu-
lated. Overall, these studies of unperturbed hematopoiesis in
animal models combined to suggest that daily hematopoiesis
is sustained by large numbers of multipotent cells, but quan-
tifying these numbers exactly remains challenging.
Transitioning to human blood
Sixty-five million years of evolutionary divergence, cou-
pled with the long life span and large size of humans,
make it difficult to extrapolate from mouse studies to
estimate human stem cell numbers and dynamics. Fur-
thermore, mice are typically studied under pathogen-
free conditions, the proportion of peripheral blood cells
that are myeloid in humans is larger, and there are
many known differences between HSCs from the two
species, including immunophenotypic definition, cyto-
kine requirements, and differences in the bone marrow
niche [30−33].
Studying human hematopoietic stem cell function
and clonal dynamics, however, comes with its own sig-
nificant experimental challenges. Historic work has
focused on xenotransplantation of tagged human cells
into animals. These studies face all the caveats of
autologous and allogeneic transplantation, with the
added complication of differences between the human
niche and that of the recipient immunocompromised
animal. Limiting dilution transplantation experiments
support the idea that thousands of bone marrow cells
have the potential to act as stem cells [34−36]. Esti-
mates of HSC number from these approaches were
divergent, which may be explained by differences in
how significantly immunocompromised the animals
were, the transplantation regimen, and the amount of
ex vivo manipulation of stem cells [37].
Notwithstanding the technical and ethical challenges,
progress has been made in directly assessing human
HSCs off the back of gene therapy trials by using the
unique genetic insertion site of the therapeutic vector
as a trackable clonal marker. These trials have pro-
vided the first opportunity to study directly the trans-
plantation and relative competitive ability of HSCs in
people. Despite the fact that analysis of viral insertion
sites is only semiquantitative, counting the number of
unique insertion sites detected years after transplanta-
tion has provided a lower bound on the number of
active stem cells in the transplantation setting. Long-
term multilineage hematopoiesis has been demonstrated
in these patients [38,39], with at least hundreds [40] to
thousands [39] of stem/progenitor cells contributing
over 2 to 4 years of follow-up.
As in the mouse, though, transplantation represents a
nonphysiological setting where HSCs demonstrate their
potential rather than their behavior in a normal unper-
turbed setting. Methods for studying native human
hematopoiesis have been based on the detection of
markers that vary naturally between different somatic
human cells. In women heterozygous for an X-linked
marker gene, detection of the proportion of cells that
have inactivated either X chromosome provides some
insight into population dynamics. In the absence of sig-
nificant selection and/or genetic drift, half of the cells
should express each X chromosome. Small imbalances,
or “XCI skewing,” that emerge with neutral genetic
drift or with selection allowed the first inferences based
on binomial statistics, which estimated a minimum
of 400 active HSCs [41]. Later work in elderly patients
revealed an increase in XCI skewing with age, and
this was used to infer the rate of clonal drift during
aging [32].
Taken together, these studies across humans reinforce
the work from animal studies that a large number of
multilineage clones drive blood production at steady
state, with the most physiological models providing
lower bound estimates of stem cell numbers. Notwith-
standing these significant advances, little is known about
unperturbed human hematopoiesis, largely because of
the absence of techniques to track large numbers of
clones individually.
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Using spontaneous somatic mutations as natural
barcodes
Somatic mutations occur in normal human cells over the
course of life, are inherited stably by their descendants,
and can be reliably detected by DNA sequencing; the vast
majority have no phenotypic effect. They can therefore
serve as excellent clonal markers. Early evidence from
exome sequencing of blood colonies indicated that muta-
tions accumulate approximately linearly over time, and at
a sufficiently high rate that whole-genome sequencing of
a blood cell should reveal multiple potential clonal
markers [42]. Uncovering the mutations present in indi-
vidual blood cells for use as clonal markers has become
feasible in recent years because of the development of
reliable methods for culturing single hematopoietic stem
and progenitor cells (HSPCs) into large colonies that pro-
duce enough DNA, as well as the significant reduction in
costs of sequencing a whole genome.
Whole-genome sequencing to track somatic
mutations
Two studies have so far exploited whole-genome
sequencing to track hematopoiesis in unperturbed
healthy humans [43,44]. Both followed broadly the
same experimental workflow of isolating single stem
and progenitor cells by fluorescence-activated cell
sorting (FACS) and expanding them in vitro into suffi-
ciently large clonal populations to permit whole-
genome sequencing with good coverage. They then
assayed different peripheral blood cell types for the
mutations that had been discovered by whole-genome
sequencing. In effect, this is similar to the inducible
cell-tagging systems discussed above, but with somatic
mutations as unique clonal tags. An important concep-
tual difference is that, unlike inducible cell-tagging
systems, which induce tags at a given timepoint and
then follow them prospectively over the course of the
experiment, somatic mutation studies assess clonal
dynamics retrospectively, with mutations that have
accumulated over time being discovered and assessed
from the end of the time course of a natural experi-
ment. Furthermore, because the mutation “tags” are
acquired continually over the course of life rather than
at one timepoint, additional information is available
from observing which tags are nested within other tags,
which informs on the clonal structure of the population
of cells. The cell types that are whole-genome
sequenced are an important consideration (Box 1).
The detection of somatic mutations is subject to both
false-positive and false-negative errors. The mutation
Box 1. Cell type matters, but not as you might expect
Sequencing any blood cell reveals mutations that mark stem cell clones
Both studies whole-genome sequenced colonies grown from primitive multipotent stem and progenitor cells.
Counterintuitively, sequencing a progenitor reveals mostly mutations that occurred in a stem cell. This is
because progenitors only relatively recently stopped being stem cells. In other words, the vast majority of muta-
tions that are discovered in a progenitor will have occurred in a cell that was behaving in vivo in a manner that
fits the conceptual definition of a stem cell. To illustrate this concept, imagine whole-genome sequencing a pro-
genitor from a 60-year-old man. Even if this progenitor is relatively long lived, it will retrace its origin to a
stem cell that existed recently (e.g., 1 year ago). Assuming a constant mutation rate from ages 0 to 60, 98%
(59/60) of mutations will have occurred in an ancestral stem cell. These mutations will therefore serve as clonal
markers for the progeny of stem cells, whether they are actually functionally assayable stem cells or not
(Figure 2A).
The mutations detected may not be representative of the whole stem cell pool
The cell types that are sequenced matter much more if stem cell clones produce biased output. This is
because they affect the way in which the stem cell pool would then be sampled. If, say, only neutrophils were
whole-genome sequenced, and some clonally related subset of the HSC pool were biased toward producing
them, clonal markers of this subset of HSCs would be overrepresented in the experiment (Figure 2B). To limit
this effect, both studies sequenced different myeloid progenitors (in addition to immunophenotypic HSCs).
Despite the attempt to minimize any skewing in reporting the complete HSC population, it must be highlighted
that the fractions isolated across both studies (HSCs, multipotent progenitors [MPPs], granulocyte−monocyte
progenitors [GMPs], megakaryocyte−erythroid progenitors [MEPs], and common myeloid progenitors [CMPs])
contain more myeloid than lymphoid progenitors in the “non-HSC” portion of cells. This may therefore result
in an underrepresentation of stem cell clones that contribute to lymphoid cell production. This was partially
addressed in one study by surveying mature lymphoid cells longitudinally to demonstrate that many branches
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detection methods used in both studies were previously
published [45,46], and several experimental results sup-
port a high specificity of the mutation calling methods.
First, the majority of mutations with a high allele frac-
tion that were discovered by whole-genome sequencing
were also detected in the recapture phase of the experi-
ments. Second, the mutation burden and mutational sig-
natures were consistent from cell to cell and between
the two experiments, implying that neither approach
dramatically skewed the type of mutation being called.
Third, the mutation burden increased linearly with the
age of subjects. The conservative mutation calling
approaches in both studies may, however, have resulted
in false-negative mutation calls. That said, as long as
false-negative errors are evenly distributed (e.g., that
mutations that occur early in life are equally likely to
be missed as those occurring later), a low sensitivity
should not skew analyses of clonal dynamics.
Depth versus breadth: Complementary studies
Lee-Six et al. [43] took the approach of studying one
individual in great depth, a healthy 60-year-old man,
from whom 140 single immunophenotypic HSPCs were
isolated by flow cytometry, grown in culture, and then
whole-genome sequenced. Most of these HSPCs were
derived from a bone marrow aspirate, but some were
from peripheral blood, to detect and avoid bias that
might result from spatial clustering of similar cells in
contributed to B lymphopoiesis. The data on T lymphocytes, however, (where many clones were underrepre-
sented compared with granulocytes and B lymphocytes) suggests the possibility that the branching structure
may not fairly represent the entirety of blood cell production.
Thus, the choice of cells to whole-genome sequence does not matter in terms of the level in the differentia-
tion hierarchy at which their mutations occurred: sequencing any blood cell will reveal mutations that occurred
in stem cells. Nonetheless, the choice of sequenced cells could affect our understanding of stem cell biases in
producing certain cell types: If we do not sequence T lymphocytes we may miss stem cell clones that are
biased toward producing them.
Figure 2. Effect of cell types that are sequenced on studies. (A) Sequencing progenitors reveals mutations that occurred in stem cells. Mutations
that occurred in stem cells accumulate over time. When a progenitor from an adult is sequenced, most of the mutations discovered occurred in
stem cells. (B) The cell types that are sequenced may affect the phylogeny that is reconstructed if stem cells do not produce balanced output. In
the top phylogeny, all stem cells produce both myeloid and lymphoid cells. Sequencing only myeloid progenitors samples the phylogeny evenly,
such that an accurate representation of the phylogeny is reconstructed. In the bottom phylogeny, some stem cells produce disproportionately
more lymphoid than myeloid progenitors. Sequencing only myeloid progenitors undersamples parts of the phylogeny that are biased toward lym-
phoid cells.
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the bone marrow. In contrast, Osorio et al. [44] opted
for breadth over depth, whole-genome sequencing 22
HSPCs from seven healthy donors, ranging in age from
0 (umbilical cord blood) to 63 years.
Detecting genomic mutations in other blood cells
The methods by which the set of somatic mutations (iden-
tified in the initial whole-genome sequencing) were
detected in other blood cell fractions also differed. Lee-
Six et al. [43] designed a bait set that included >7,000
mutations that had been discovered in the initial sample
set and used it for ultradeep-targeted sequencing (range:
268£ to 4669 £) of bulk peripheral blood cell fractions
across different timepoints. Osorio et al. [44] genotyped
125 further colonies and analyzed the presence or absence
of 13 mutations in different blood cell fractions from one
patient. Despite these differences in design, the findings
of the two studies (Table 1) are similar. Below we discuss
their implications.
Inferences about the development of blood
Both studies used the somatic mutations discovered in
individual HSPCs to build a family tree of how the
cells were related to one another. Figure 3 illustrates
the structure of the phylogenetic trees from both stud-
ies. The smaller phylogeny of Osorio et al. [44] was
constructed manually by inspecting the pattern of muta-
tion sharing between cells. The phylogeny in Lee-Six
et al. [43] was reconstructed computationally using
methods that aim to identify the tree that is most likely
to produce the observed set of combinations in which
somatic mutations are shared between different individ-
ual cells, based on a model of how somatic mutations
are acquired and detected. The phylogeny was then val-
idated using orthogonal methods (the range of methods
that can be used to construct phylogenies is discussed
in Yang and Rannala [47]). In each case, the majority
of the branchpoints in the phylogenies occur at the top
of the tree. As you look up toward the root of the
phylogenies, you are looking back in time, and the ear-
liest branchpoints tell us about cell divisions that
occurred in the embryo. That most branchpoints in
both trees occur early is probably due to that fact that
when a relatively small sample is drawn from a large
population, cells are likely only to be distantly related
and so will share only embryonic branchpoints. A rapid
population expansion in the embryonic phase, or other
population size changes over life, may also contribute
to this effect, however. Both studies found the muta-
tions on these earliest branches also to be present in
cells from other germ layers (mesenchymal stem cells
in Osorio et al. [44], buccal epithelium in Lee-Six
et al. [43]), indicating that these mutations and branch-
points must occur early in embryogenesis. The daugh-
ters of the very first were found to contribute unevenly
to blood, with one daughter ancestral to approximately
two-thirds of the sampled cells and one ancestral to
approximately one-third of the sampled cells. This sup-
ports similar findings in the mouse [47] and in bulk
sequencing of human blood [48]. The Lee-Six et al. [43]
study found that the mutation on one side of the first divi-
sion that was present in two-thirds of blood cells was also
present in two-thirds of cells from the buccal swab, and
the mutation on the other side present in one-third of
blood cells was present in one-third of buccal cells. This
indicates that the common ancestor of blood was the
same as the common ancestor of buccal cells, which
derive from another germ layer, a finding that indicates
that this common ancestor must have existed very early in
development, perhaps as far back as the fertilized egg.
Estimating HSC numbers
The size of the family tree of cells in one study permit-
ted further analysis of stem cell dynamics by borrowing
methods from population genetics. In epidemiology,
the pattern of branching in a phylogeny of influenza
genomes can be used to reconstruct the population his-
tory of the virus, showing that the population size
Table 1. Common findings from the two studies
Lee-Six et al. [43] Osorio et al. [44]
Clonal contributions
to blood production
50,000−200,000 stem cells make granulocytes at
any one time.
Each of 13 clonal markers were found in differentiated blood
cells.
Lineage output of
clones
The majority of HSC clones responsible for mye-
loid blood production also made B lymphocytes,
but not T lymphocytes.
HSC clones were ancestral to all of granulocytes, erythroblasts,
megakaryocytes, and B cells.
Embryonic specifica-
tion of blood
The common ancestor of blood occurs before gas-
trulation. The daughters of this common ancestor
contribute unequally to blood.
The daughters of the common ancestor of blood contribute
unequally to blood.
Mutation rate and
patterns of HSCs
Based on one patient, mutation rate is »17 muta-
tions per year. Blood mutations occur in a char-
acteristic trinucleotide context.
Based on patients of different ages, mutation rate is constant and
occurs at 14.2 mutations per year. Mutational signature analysis
reveals a signature of blood production with features consistent
with the trinucleotide context of Lee-Six et al. Its transcrip-
tional strand bias suggests that it is due to guanine adducts.
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increases in winter and drops in summer [49,50]. A
phylogeny of a constant population size exhibits an
expected distribution of branchpoints. If the population
size increases, branchpoints increase in density around
the time of the increase, and if there is a bottleneck,
branches are pruned from the tree, resulting in a
coppiced appearance (Figure 4). One of the attractive
features of data sets generated by whole-genome
sequencing is that methods developed for the fields of
epidemiology, ecology, and population genetics can
each be utilized.
When a phylodynamic inference program is applied
to the tree structure of cells, a logarithmic increase in
population size is observed early in life, consistent
with the rapid growth of the HSC pool needed during
embryogenesis and early childhood, followed by decel-
eration in the rate of increase, reaching a plateau in
adulthood. If the mutation rate per year in HSCs is
higher during development, as it may conceivably be
to expand the stem cell pool, then this plateau will
be reached before adulthood. The immunophenotypic
stem cell pool (LinCD34+CD38CD90+CD45RA)
has been reported to increase with old age [51], but, as
has been suggested in mice, the functional stem cell
pool may not [52,53]. Phylodynamic methods should
report on the effective population size, which relates to
the stem cell pool that is able to self-renew. It remains
to be seen whether phylodynamic methods support an
increase in HSC population size over the age of 60.
This could be tested by repeating the study in older
individuals.
Measuring persistent clonal contribution to mature
cell populations
Detecting clonal markers in differentiated blood cell
types reveals which stem cell clones have progeny at
the time of sampling. If only a subset of clones were
making granulocytes, only the markers of those clones
would be detected in the deep sequencing data of gran-
ulocytes. However, both studies found that markers
Figure 3. Phylogenies from (A−C) Lee-Six et al. [43] and (D−F) Osorio et al. [44]. (A) The phylogeny of cells is shown in gray, with branch
lengths proportional to the numbers of somatic mutations (y-axis). Each tip of the phylogeny leads to a stem or progenitor cell that has been
whole-genome sequenced. Information from targeted sequencing of peripheral blood granulocytes is overlain. This is shown more clearly in the
inset (B), which zooms in on one portion of the tree. On top of the underlying structure of the phylogeny (gray) are placed horizontal bars.
Each bar represents a mutation in the bait set for targeted sequencing. The bars are colored according to the proportion of cells in the sample
that carry the mutation, indicated by the color scale. Undetectable mutations are colored gray and shown as smaller bars. Mutations are assigned
to a branch based on the colonies in which they are present. (C) This schematic explains that the allele fractions of targeted mutations in periph-
eral blood decline down the branches because of undetected coalescences with stem cells that were not whole-genome sequenced, but are pro-
ducing granulocytes. (D) The phylogeny of whole-genome sequenced clones. Branches are labeled a−m, each of which represents a mutation
that defines the lineage. The presence (hematopoietic stem cells: black, multipotent progenitors: dark gray) or absence (pale gray) of each muta-
tion in genotyped clones is shown in the panel below the phylogeny. (E) Continuation of the phylogeny for whole-genome sequenced clones,
with branch lengths proportional to mutation load. (F) Allele fractions of mutations a−m in mature blood cell populations.
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Figure 4. Simulations illustrate that phylogenies reflect the population size trajectory. All simulations were produced using a Fisher−Wright
model of neutral drift. At the end of each simulation, 100 cells are sampled and their phylogeny reconstructed. (A) A constant population size.
(B) A sudden strong bottleneck in population size at the point in time indicated by the red dashed line. (C) An increase in population size
between the red dashed lines, which stabilizes thereafter.
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from multiple nonnested clones were present in differ-
entiated blood cells from each given time point
(Figure 3). In other words, the production of blood is
highly polyclonal, deriving from a large number of
HSCs. If clonal markers are arranged on the phyloge-
netic tree (Figure 3A−C) one can see that mutations
higher up the tree (i.e., those that occurred earlier in
time) are present in a greater proportion of HSCs. This
makes sense, as mutations lower down the tree
occurred in nested clones: they are necessarily present
in fewer cells. Rapidly, as one progresses down the
tree, the mutations are present in such a small propor-
tion of cells that they are no longer detectable, even
with deep sequencing. This means that the mutations in
early clones that are detectable will be present in many
descendants, and so blood must be produced by many
more stem cells than the number of clones apparent in
Figure 3.
With some assumptions and a relatively simple
model of hematopoiesis (Box 2), one can use the tar-
geted sequencing data to estimate the number of HSCs
that sit at the bottom of the tree and are ancestral to
the blood sample. This is explained more formally in
Lee-Six et al. [43], but in brief, the estimate comes
from comparing targeted sequencing counts of each
mutation in different granulocyte samples taken at the
same time from the same individual. The number of
mutant reads in each of the granulocyte samples is a
proxy for the number of cells in that granulocyte sam-
ple that carried the mutation. If one knows the number
of granulocytes in each sample, and the number of
them that carry the mutation, one can adapt the logic
of capture−recapture methods to estimate the number
of stem cells (similar to how ecologists estimate popu-
lation size by tagging animals in the wild [capture] and
then recapturing animals at a later point and asking
what proportion of them are tagged). Imagine that only
10 stem cells contributed to blood at any one time, and
we have 100,000 granulocytes in each of two samples.
We would expect all mutations from all 10 stem cells
to be found in both granulocyte samples. Now consider
that one million stem cells make blood at any one
time, and we still have 100,000 granulocytes in each
sample. It is not possible for mutations that are private
to each of the one million stem cells to be found in
any given granulocyte sample, as the number of granu-
locytes is smaller than the number of stem cells. Under
the framework of an approximate Bayesian computa-
tion in an attempt to recapitulate the complexity of
human hematopoiesis and the experimental setup, it
was possible to estimate that 50,000−200,000 HSCs
make granulocytes at any one time.
Considering the data from both articles, it therefore
seems highly likely that hematopoiesis in humans is
hugely polyclonal, as previously suggested by animal
and transplantation studies, but perhaps to an even
greater degree than had been anticipated.
Multilineage hematopoiesis: Multipotent clones are
dominant in humans in vivo
Detecting a mutational marker in multiple differenti-
ated blood cell types means that the cell that acquired
that mutation had descendants that were capable of
producing all of these cell types. Both studies found
Box 2. Simulated model of hematopoiesis
Lee-Six et al. [43] chose an approximate Bayesian computation approach to estimate the number of stem cells
[71]. This involves simulating a model of hematopoiesis thousands of times, while changing the number of
stem cells in each simulation and recapitulating the whole experiment in silico for each simulation. The number
of stem cells for the simulations that produce results most similar to the observed data are considered to be
most probable. The model was chosen to be as simple as possible:
1. The size of the stem cell pool was constant over adult life.
2. Individual stem cells within the population of total stem cells replicated stochastically over life, and their
clonal dynamics approximated neutral drift. There was no selection in the model, and the pool was consid-
ered to be homogeneous (i.e., there were not more or less quiescent compartments).
3. In each cell division, each stem cell acquired a number of mutations drawn from the Poisson distribution.
Mutation rate was constant over life.
4. All of the stem cells with which the simulation was concerned were ancestral to a similar number of granu-
locytes.
A variable mutation rate per year during development could have affected estimates of stem cell number. To
avoid this, only mutations that had occurred after 100 mutations of molecular time, and so after the phase of
population expansion, were used in this analysis.
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mutations that were shared in multiple blood cell types.
Osorio et al. [44] found four mutations that were not
shared with mesenchymal stem cells (and so are likely
to have occurred after gastrulation) but were each
detected in multiple differentiated blood cell types,
including combinations of granulocytes, megakaryo-
cytes, erythroblasts, and B lymphocytes (T lympho-
cytes were not assayed) (mutations j, l, m, and g in
Figure 3F). Thus, all hematopoiesis-specific clones that
they could detect were multipotent.
Lee-Six et al. [43] assayed granulocytes and B and
T lymphocytes for mutations found by whole-genome
sequencing. Mutations that occurred very high up the
phylogeny, and so occurred in the embryo or early life,
were shared by all three cell types. Later mutations,
including ones occurring sufficiently far down the phy-
logeny that they are likely to have occurred in early
adulthood, were shared by both granulocytes and B
lymphocytes, indicating an ongoing contribution of
multipotent adult HSCs to B lymphopoiesis throughout
life. These mutations were, however, commonly absent
from T lymphocytes. Possible explanations for this
absence include the following:
1. There may be clones that skewed toward the pro-
duction of granulocytes and B cells but not T cells.
This may be because the colonization of the thymus
is a process driven by a relatively small proportion
of cells.
2. It may reflect the longevity of the T-cell pool. If
most T cells matured in the thymus earlier in life,
the clonal markers found in the T-cell pool would
represent the stem cells that existed many decades
ago rather than those contributing today.
Whatever the explanation, the limited sampling of
the HSC pool means that the presence of clones that
produce all three cell types cannot be excluded. Fur-
thermore, the studies’ sampling strategies mean that
clones that produce only lymphoid cells are likely to
be missed (Box 1). More extensive sampling—at the
whole-genome sequencing stage—of HSCs and of dif-
ferent peripheral blood cell fractions, including T lym-
phocytes and their precursors, as well as repetition of
the experiment in patients of different ages, may help
to clarify the cause of the divergence in ancestry of B
and T lymphocytes. Similarly of interest, Osorio et al.
[44] found mutations that were at higher allele frac-
tions in each differentiated blood cell type than in
megakaryocytes and, conversely, mutations that were at
higher allele fractions in megakaryocytes than in other
differentiated blood cell types, suggesting that mega-
karyocytes might diverge early and be sustained by a
specific set of HSC clones. Ultimately, all blood cell
types may be analyzed in this way, and their
comparison may help to elucidate clonal hierarchies of
lineage restriction, by analogy to experiments in mice..
Further genomic insights
As a useful by-product to clonal tracking, whole-
genome sequencing of blood stem and progenitors
reveals a wealth of information about their genomes,
with implications for our understanding of normal
blood cells and leukemias. For example, the analysis of
individuals of different ages by Osorio et al. [44]
revealed a linear mutation accumulation with age, at
the rate of »14 base substitutions per year, consistent
with the »1,000 mutations seen in a 60-year-old in
Lee-Six et al.’s study and previous studies of normality
and malignancy [42,54].
Interestingly, the mutation burden found from bulk
sequencing myeloid leukemias is not elevated relative
to normal cells. Indeed, the mean number of mutations
per AML genome in a cohort with a mean age of 55
was just over 400 [55]. Some of the difference between
normal and cancer may be due to different sequencing
platforms, mutation calling algorithms, or contamina-
tion of the matched normal tissue with leukemic blasts
(such that somatic mutations appear to be germline).
Another, potentially more biologically interesting,
explanation is that the most recent common ancestor of
the leukemia may have existed a long time ago: if a
single leukemic cell were sequenced, it might have the
same mutation burden as a single normal cell, but bulk
sequencing misses a large proportion of the subclonal
mutations in the tumor [56]. Depending on the strength
of the effect of the first three factors, comparison with
normal data could indicate that the most recent com-
mon ancestor of many AMLs occurred decades before
diagnosis.
Additional genomic insights come from analysis of
the pattern of mutations across the genome, where so-
called “mutational signatures” can provide clues to the
etiology of the processes causing them [57,58]. Single-
base substitutions can be divided according to the iden-
tity of the original and resultant base into six types:
C>A, C>G, C>T, T>A, T>C, T>G. Certain processes
are associated with an excess of one type over the
other. For example, smoking is associated with C>A
changes. Examining one base upstream and one base
downstream of the mutated base (the trinucleotide con-
text) provides further resolution. The substitutions
found in normal blood [43,44], clonal hematopoiesis
[59], and certain leukemia genomes [60] have a distinc-
tive pattern of trinucleotide substitutions. Osorio et al.
[44] deconvoluted these mathematically into three dis-
tinct processes: signatures 1 and 5, ubiquitous signa-
tures that accumulate in a clocklike manner over life in
most tissues [54], and a signature that had a transcrip-
tional strand bias with more C>T mutations on the
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transcribed strand. If, as is usually thought to be the
case, this is a result of transcription-coupled nucleotide
excision repair, this signature would be consistent with
the repair of damage caused by a guanine adduct. With
further characterization and additional samples, muta-
tional signatures will be of significance to our under-
standing of hematopoiesis because they may in some
cases report time spent in specific microenvironments.
For example, one could imagine that particular features
of the bone marrow microenvironment might protect
cells from certain mutational process or caused others
and that time spent in the bone marrow (or away from
it) would then be revealed by analyzing mutational sig-
natures.
Comparison with other tissues
In recent years, many nonhematological normal human
tissues have been investigated by sequencing. In most
cases, the principal insights have been to catalogue the
burden and range of somatic mutational processes and
to describe the presence and effect of different driver
mutations that characterize different histologically nor-
mal human tissues [61−68]. In comparison to the other
tissues studied so far, blood has a relatively low muta-
tion rate, and the set of mutational processes acting in
HSCs seems to be more restricted than in other tissues
studied to date.. For example, the average mutation
rate per year in colonic stem cells is at least twice that
of HSCs, and the diversity of mutational processes is
greater [46,65]. This may be related to stem cell divi-
sion rates, cell-specific DNA repair mechanisms, and
differences in mutational exposures between different
stem cell environments.
Inferences about the stem cell dynamics of normal
tissues may also be drawn from experiments on
sequencing of solid tissues. Unlike in the blood, which
presents the unique opportunity of relatively random
sampling of cells because of its liquid nature, studying
the clonal dynamics of solid tissues requires assump-
tions about how clones grow and shrink in space.
Nonetheless, important insights may be gained with
simple models of development and stem cell dynamics.
Patterns of embryonic development may be mapped out
through careful reconstruction of phylogenies and com-
parison with anatomical location of the sequenced cells
[48,63,64]. The growth of clones may be detected by
sequencing microbiopsies of tissues and estimating
clone size from allele fractions [61,62]. In the colon,
the crypt fission rate and the time to monoclonal con-
version within a crypt may be estimated [65,69]. A bet-
ter understanding of how cells distribute themselves
within a tissue may be necessary, however, before solid
tissues can be studied to the same resolution as the
blood. In contrast, solid tissues have led the way in
demonstrating that sequencing can reveal the effect of
various stressors on clonal dynamics. Whole-genome
sequencing of human liver [66] and lung [70] reveals
the changes in stem cell architecture associated with
alcohol and obesity for the liver and smoking for the
lung, helping to elucidate how stem cells behave under
different pressures. Similar studies will be possible in
the blood and should be undertaken within the coming
years to assess the resiliency of the system to various
mutational processes.
Concluding remarks
Somatic mutations provide a flexible and powerful way
to investigate unperturbed hematopoiesis. The insights
gained range from clonal structure and lineage outputs
to insights into the embryonic development and
mutational landscapes of the blood. Whole-genome
sequencing as a method to track unperturbed human
hematopoiesis is a natural extension of decades of
work in animal models using different markers to fol-
low cells and opens opportunities for having a more
direct assessment of what HSCs actually do in vivo
throughout aging. It has been made possible by techno-
logical advances, and will become increasingly tracta-
ble as the cost of sequencing declines further and the
amounts of input DNA required fall, such that shorter
in vitro amplification phases, and eventually no in vitro
amplification phases, are necessary to detect mutations
reliably. This will allow whole-genome sequencing of
all blood cell types. A wide array of future experiments
suggest themselves to exploit this technology. Small
numbers of individuals have so far been studied, and
the person-to-person variability in all of the described
parameters remains to be explored before general con-
clusions can be made. As many hematopoiesis-related
disorders present in old age, following patients longitu-
dinally for decades will reveal all stages of the changes
in clonal structure associated with clonal hematopoiesis
and malignancies, including the discovery of multiple
genetic ways to arrive at the same physiological or
pathophysiological state. One could also imagine that
defining the clonal landscapes of a background popula-
tion and comparing it with those in the early stages of
malignancy may allow the early identification of risk
of malignancy in a more robust manner than age-
related clonal hematopoiesis. Eventually it may even
become possible to intervene to avert clonal outgrowths
by supporting clones with a lower propensity to drive
leukemia or targeting those that associate with malig-
nancy. In all cases, more extensive cell sampling,
sequencing different cell populations (e.g., mature lym-
phoid cells), and combining sequencing of genomes
with that of transcriptomes could provide further infor-
mation on exactly which clones produce which cells
and how they are related to one another.
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